Aim: The clinical application of cisplatin is limited by severe side effects associated with high applied doses. The synergistic effect of a combination treatment of a low dose of cisplatin with the natural alkaloid α-solanine on human hepatocellular carcinoma cells was evaluated.
Methods: HepG2 cells were exposed to low doses of α-solanine and cisplatin, either independently or in combination. The efficiency of this treatment modality was evaluated by investigating cell growth inhibition, cell cycle arrest, and apoptosis enhancement.
Results: α-solanine synergistically potentiated the effect of cisplatin on cell growth inhibition and significantly induced apoptosis. This synergistic effect was mediated by inducing cell cycle arrest at the G2/M phase, enhancing DNA fragmentation and increasing apoptosis through the activation of caspase 3/7 and/or elevating the expression of the death receptors DR4 and DR5. The induced apoptosis from this combination treatment was also mediated by reducing the expression of the anti-apoptotic mediators Bcl-2 and survivin, as well as by modulating the miR-21 expression.
Conclusion: Our study provides strong evidence that a combination treatment of low doses of α-solanine and cisplatin exerts a synergistic anticancer effect and provides an effective treatment strategy against hepatocellular carcinoma.
[http://dx.doi.org/10.1200/JCO.2017.76.0892] [PMID: 29498924]
[http://dx.doi.org/10.1142/S0192415X09006758] [PMID: 19222120]
[http://dx.doi.org/10.1007/s13277-015-4528-2] [PMID: 26631041]
[http://dx.doi.org/10.1016/j.jphotobiol.2016.08.009] [PMID: 27533849]
[http://dx.doi.org/10.1016/j.pdpdt.2013.03.013] [PMID: 24284098]
[http://dx.doi.org/10.1038/cddis.2016.138] [PMID: 27253411]
[http://dx.doi.org/10.1002/cam4.916] [PMID: 27726305]
[http://dx.doi.org/10.1021/bi00324a025] [PMID: 4039603]
[http://dx.doi.org/10.1002/(SICI)1097-0320 (19970101)27:1<54:AID-CYTO7>3.0.CO;2-L] [PMID: 9000585]
[http://dx.doi.org/10.1254/fpj.136.198] [PMID: 20948154]
[http://dx.doi.org/10.1016/j.arcmed.2011.01.006] [PMID: 21376256]
[http://dx.doi.org/10.3390/molecules190811896] [PMID: 25116803]
[http://dx.doi.org/10.3389/fphar.2018.01307] [PMID: 30483138]
[http://dx.doi.org/10.1111/j.1742-1241.2008.01777.x] [PMID: 18479363]
[http://dx.doi.org/10.1016/j.canlet.2011.10.012] [PMID: 22079466]
[http://dx.doi.org/10.3892/ijmm.2012.1208] [PMID: 23233126]
[http://dx.doi.org/10.2165/00063030-200721050-00002] [PMID: 17896836]